Proton pump inhibitors, osteoporosis, and osteoporosis-related fractures
This trend should encourage brands to proactively reformulate to meet these emerging standards and capture shelf space in this growing category
Number of Patients on GLP-1 Number of patients on GLP-1, whether for diabetes or obesity, has tripled in the last three years thanks to Novo Nordisk and Eli Lilly.
Available evidence from diabetes and obesity trials demonstrates substantial weight regain after discontinuation of GLP-1 RAs, reaching pre-treatment levels in some cohorts within 12-18 months of cessation, with accompanying deterioration in cardiometabolic parameters [72]
The choice of chelation therapy may depend on the efficacy and safety of the regimen
Mounjaros prescribing information states that the medication delays gastric emptying and has been associated with gastrointestinal adverse reactions, sometimes severe